ERS Genomics and Sai Life Sciences Sign CRISPR/Cas9 Deal
ERS Genomics and Sai Life Sciences Sign CRISPR/Cas9 License Deal for Precision Genome Editing in Drug Development.
CRISPR/Cas9 License Agreement | 23/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy